The abstract is read at the publisher; the summary is JClub's.
An 8-week bemnifosbuvir–ruz asvir regimen achieved 90% SVR12 (248/275) in treatment-naïve chronic hepatitis C patients across genotypes, including those with compensated cirrhosis.
- Why it matters: Short, pan-genotypic options are needed for chronic HCV, especially for patients with baseline NS5A resistance-associated substitutions and compensated cirrhosis where treatment response can be harder.
- What they did: In a single-arm Phase 2 trial, patients received bemnifosbuvir 550 mg plus ruzasvir 180 mg once daily for 8 weeks, and SVR12 was measured 12 weeks after treatment in PK/PC-PP, EE-PP, and ITT populations.
- The result: SVR12 was 98% (210/215) in PK/PC-PP and 95% (245/259) in EE-PP, with 5 post-treatment relapses in PK/PC-PP and no drug-related serious adverse events or drug-related early discontinuations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.